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 Abstract 
Objective: Historically, a set of 5 cardiovascular autonomic reflex tests (CARTs) was 
considered to be the gold standard in the assessment of cardiovascular autonomic neuropathy 
(CAN). However, measuring diastolic blood pressure (BP) response to sustained handgrip is 
omitted in recent guidelines. We aimed to assess the association between the handgrip and the 
other 4 tests as well as to identify determinants of the handgrip test results in diabetic patients. 
Patients and methods: 353 patients with diabetes (DM) were recruited (age: 60.2±7.4 years; 
female: 57.2%; BMI: 29.3±2.1 kg/m2; DM duration: 15.6±9.9 years; HbA1c: 7.8±1.4% (66 
mmol/mol); with type 1 DM: 18.1%). CAN was assessed by 5 CARTs: the deep breathing 
test, Valsalva ratio, 30/15 ratio, handgrip and orthostatic hypotension test. 
Results: Sensitivity and specificity of the handgrip test in the diagnosis of definite CAN were 
24.6% (95%CI 17.7-33.1%) and 79.4% (95%CI 73.3-84.4%), respectively. Results of the 
handgrip test did not show any association with those of the deep-breathing test (γ=0.004, 
p=0.563), 30/15 ratio (γ=0.282, p=0.357), Valsalva ratio (γ=-0.058, p=0.436) and orthostatic 
hypotension (γ=-0.026, p=0.833). Handgrip test abnormality showed an independent 
association with higher initial diastolic BP (OR 1.05, p=0.0009) and an independent inverse 
association with the presence of hypertension (OR=0.42, p=0.006).  
Conclusions: Our data confirm that the handgrip test should no longer be part of the 
cardiovascular autonomic testing being highly dependent on hypertensive status and baseline 
diastolic BP. Exaggerated exercise pressor response is proposed as putative mechanism for 
the inverse association between abnormal results of the handgrip test and hypertension. 
Adequate CARTs important to allow their use in clinical trials and for the prevention of DM-
associated complications by initiating early treatment.  
Keywords: diabetes, cardiovascular autonomic neuropathy, handgrip test, hypertension 
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Abbreviations: 
ABPM: ambulatory blood pressure monitoring; ACE inhibitor: angiotensin-convertase 
enzyme inhibitor; BP: blood pressure; CAN: cardiovascular autonomic neuropathy; CART: 
cardiovascular reflex test; CI: confidence interval; COPD: chronic obstructive pulmonary 
disease; DM: diabetes mellitus; ECG: electrocardiogram; LnLF day: daytime low-frequency 
power; NS: not significant; OHT: orthostatic hypotension test; OR: odds ratio 
 
Cardiovascular autonomic neuropathy (CAN) is a common complication of diabetes mellitus 
(DM). Its prevalence varies between 7 and 65% depending on the diagnostic criteria and the 
studied population increasing with age and DM duration [1]. Moreover, it may be present in 
newly diagnosed patients with type 1 and type 2 DM and in patients with impaired glucose 
tolerance [2]. A meta-analysis of 15 longitudinal studies with a follow-up of 1-16 years 
showed that the definite diagnosis of CAN based on at least 2 abnormal test results is 
accompanied by a relative risk of mortality of 3.65 [3]. The association between CAN and 
cardiac death, non-fatal myocardial infarction and silent ischaemia is well-known [4]. CAN 
was associated with left ventricular dysfunction and hypertrophy in patients with DM type 2 
in whom cardiac disease was absent [5]. QT prolongation may lead to severe ventricular 
arrhythmias and a 2-fold risk of stroke [5]. There is emerging evidence that CAN is an 
independent predictor of the development and progression of diabetic nephropathy [6, 7]. 
Therefore, early diagnosis of CAN and thereby identifying patients at high risk of 
cardiovascular morbidity and mortality is crucial. In clinical practice, assessment of CAN is 
usually based on the cardiovascular reflex tests (CARTs) standardized by Ewing et al. [8]. 
CARTs are safe, non-invasive, clinically relevant, reproducible and easy-to-perform. Hence, 
they are widely used and considered gold standard measures of CAN [9, 10]. The San 
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Antonio Consensus conference advocated that a battery of quantitative tests including both 
parasympathetic and sympathetic function tests should be performed and more than one of 
these tests should be abnormal to verify the diagnosis of CAN [10]. The need to use more 
tests has been confirmed in recent guidelines [1, 11]. However, measuring diastolic blood 
pressure (BP) response to sustained handgrip is no longer recommended as an established 
clinical test [1, 9]. According to the Therapeutics and Technology Assessment Subcommittee 
of the American Academy of Neurology, the handgrip test has limited sensitivity and 
specificity in diagnosing CAN [9]. Furthermore, little attention has been paid to confounding 
variables influencing the result of handgrip test and evidence is lacking to judge its clinical 
usefulness. 
The aim of our study was to assess the diagnostic value of the handgrip test in detecting CAN. 
Furthermore, we evaluated the relationship of handgrip test results with results of the other 
CARTs and investigated the factors influencing the diastolic BP response to sustained 
handgrip exercise in patients with DM. 
 
Research design and methods 
The present cross-sectional study was carried out in patients with DM attending the 1st 
Department of Medicine, Semmelweis University, Budapest, Hungary. Inclusion criteria were 
the presence of type 1 or type 2 DM according to the WHO (1999) criteria [12]. Patients 
hospitalized for acute intercurrent diseases (fever, infection, etc.) or for acute metabolic 
derangements such as diabetic ketoacidosis or hyperglycaemic hyperosmolar state were 
excluded from our study. Further exclusion criteria included diseases or conditions that may 
affect autonomic function, such as thyroid and liver diseases, chronic kidney failure, 
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autoimmune or haematological disorders, Parkinson’s disease, etc. Subjects with a history of 
arrhythmia, bundle branch block, heart failure, valvular disease, acute coronary syndrome, 
ischaemic heart disease or pulmonary disorders (COPD) were also excluded. Patients with 
DM with poor physical status making them unable to perform sustained isometric muscular 
strain and patients with proliferative retinopathy being at risk of intraocular haemorrhage 
during Valsalva and handgrip manoeuvre were also not included. 
Eligible patients were requested to avoid strenuous physical exercise, caffeine beverages, 
smoking and alcohol in the 12h preceding cardiovascular autonomic testing. Patients taking 
antihypertensive agents that might influence the results of the CARTs based on heart rate 
changes were asked to omit interfering medication, particularly beta-receptor blockers and 
non-dihydropyridine-type calcium channel blockers in the 24h interval before CARTs were 
performed. 
All participants gave informed consent and the study protocol was approved by the local 
ethics committee. 
Data on age, glycaemic control (HbA1c), DM duration, antidiabetic and antihypertensive 
medication, insulin treatment, use of diuretics and presence of neuropathic pain requiring 
specific pain-relieving medication were obtained. Weight and height of eligible subjects were 
measured and body mass index (BMI) calculated (expressed in kg/m2). Measurements of 
office BP and BP values during the manoeuvres were accomplished using an OMRON M2 
(Omron Corporation, Kyoto, Japan) automatic upper hand-cuff sphygmomanometer. Office 
BP values were obtained after a minimal period of 5 min of resting state  and  the average of 
three seated BP measurements was determined. 
Cardiovascular autonomic function was assessed by the 5 CARTs using Cardiosys 12.1 
diagnostic station and Cardiosys-A01 software (MDE Heidelberg GMBH, Heidelberg, 
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Germany). During real-time 12-lead monitoring recorded ECG signals were digitized at 2000 
Hz sampling rate with a multichannel data acquisition system connected to a personal 
computer. Stored data were available for off-line analysis. 
CARTs based on heart rate changes mainly reflect parasympathetic function while those 
based on BP response to manoeuvres explore sympathetic function. 
The result of the deep-breathing test was expressed as the difference of the highest heart rate 
during inspiration and the lowest heart rate during expiration (beat-to-beat variation; 
beats/min). 
Valsalva ratio was assessed as follows: participants were instructed to blow into the mouth 
piece of Cardiosys connected to the computer and to maintain 40 mmHg airway pressure for a 
period of 15 sec according to the standardised protocol. The ratio of the longest RR interval 
after and the shortest RR interval during the manoeuvre was measured. 
Result of the orthostatic hypotension test (OHT) was defined as the difference between the 
systolic BP measured at rest in supine position and the lowest systolic BP after arising. 
30:15 ratio was computed as the ratio of the RR intervals of the 30th and 15th (or nearby) 
cycles following standing up. 
Subjects performed sustained handgrip exercise at 30% of maximal voluntary contraction up 
to 3 min. BP values were measured before the test (initial or baseline diastolic BP) and each 
minute in the 3 min period during sustained handgrip exercise. 
To evaluate severity of cardiovascular autonomic dysfunction, an overall autonomic 
neuropathy score (CAN score) was obtained by scoring the results of the reflex tests: 0, 1 and 
2 for normal, borderline and abnormal test result, according to age-related reference values for 
heart rate based tests [13].  
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Similarly, a parasympathetic impairment score was derived from the results of the 
parasympathetic function tests based on heart rate changes [1]. Normal results of a test were 
scored with 0, borderline results with 1, and abnormal results with 2. 
Confirmed diagnosis of CAN was defined as the presence of ≥2 abnormal test results as 
recommended by recent guidelines [13]. 
 
2.3. Statistical analysis 
The Kolmogorov-Smirnov test for normality was performed on all variables. Normally 
distributed data are expressed as mean ± SD while non-normally distributed variables are 
described as median/geometric mean and interquartile range.  
To evaluate the diagnostic accuracy of the handgrip test vs diagnosis of confirmed CAN 
(presence of ≥2 different abnormal test results), sensitivity and specificity were determined 
using 2x2 contingency tables and χ2 test. Categorical variables are reported as n (%). 
Since most results of CARTs were not normally distributed, association between the results of 
the handgrip test and clinical parameters were analysed using Spearman’s rank correlation 
(rho). Kruskal’s monotony coefficient gamma (γ), also known as the Goodman-Kruskal test, 
was used to evaluate the association between abnormality of the handgrip test and 
abnormality of the other tests. For comparison between groups with normal and abnormal 
handgrip test result, the Mann-Whitney U-test or paired t-test for continuous variables and χ2 
test or Fisher’s exact test for categorical data were performed as required. 
In order to adjust for the confounding effect of antihypertensive medication on the association 
between handgrip test results and hypertension as well as the association between handgrip 
test results and initial diastolic BP, additional multiple logistic regression analysis was 
performed. Variables associated (p < 0.1) with abnormal handgrip test result were included in 
this analysis. 
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All analyses were performed using STATISTICA 12.5 software (Statsoft Inc, Tulsa, USA). 
Statistical significance was defined as p < 0.05 (two-sided value). 
 
Results 
A total of 353 diabetic patients were included: 64 (18%) with type 1 and 289 (82%) with type 
2 DM; 225 (63.7%) patients had coexistent hypertension (30 with type 1 and 195 with type 2 
DM). Hypertensive subjects had known hypertension and were taking antihypertensive 
medication. The main characteristics of the study population are shown in Table 1. 
Diagnosis of CAN was present in 36.8% of the patients. Abnormal results of the deep-
breathing test, the Valsalva ratio, 30/15 ratio, handgrip and orthostatic hypotension test were 
proven in 59.5, 19.5, 4.5, 22 and 32.3%, respectively.  
Compared with the definition of CAN based on the presence of at least 2 abnormal reflex 
tests, sensitivity of the handgrip test for detecting CAN was 24.6% (95% CI 17.7 - 33.1%) 
and specificity was 79.4% (95% CI 73.3 - 84.4%) (p = 0.384). Abnormal results of the 
handgrip test did not show any association with abnormality of the deep-breathing test (γ = 
0.004, p = 0.563), Valsalva ratio (γ = - 0.058, p = 0.436), 30/15 ratio (γ = 0.282, p = 0.357) 
and the parasympathetic impairment score (γ = 0.059, p = 0.465), respectively. An association 
between results (scores) of the handgrip and the OHT failed to be proven (γ = - 0.026, p = 
0.833) [Table 2]. For comparison, associations of the three parasympathetic tests, as well as 
parasympathetic score with OHT are also shown in Table 2.  
In order to identify factors influencing handgrip test results, patients with and without 
handgrip test abnormality were compared in terms of demographic and clinical 
characteristics. Patients with abnormal handgrip test result had significantly higher mean 
office systolic BP (140 vs 130 mmHg, p = 0.007) and higher mean baseline diastolic BP (83 
vs 76 mmHg, p = 0.0004) than those with normal handgrip test result. In contrast, diagnosis of 
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hypertension was more frequent in patients without handgrip test abnormality [186 (67.7%) vs 
39 (50%), p = 0.0076] [Table 3].  
Diastolic BP changes during handgrip test correlated negatively to baseline diastolic BP 
values (rho = - 0.286, p < 0.01), while office systolic BP had no effect (rho = - 0.0169, NS) on 
the scale of BP increase during handgrip test. In multiple logistic regression analysis, 
handgrip test abnormality was related to the initial diastolic BP values (OR: 1.05, 95% CI: 
1.02 - 1.08; p = 0.0009) and inversely related to the presence of hypertension (OR: 0.42, 95% 
CI: 0.23 - 0.78, p = 0.006), with these relationships being independent of antihypertensive 
medication [Table 4]. 
Abnormal results of the OHT test (defined as a systolic BP fall of at least 20 mmHg) were 
influenced neither by clinical characteristics such as age (rho = 0.059, NS), BMI (rho = 0.122, 
NS), DM duration (rho = - 0.102, NS), HbA1c (rho = - 0.139, NS), baseline systolic BP (rho 
= - 0.109, NS) nor by the presence of hypertension (χ² = 0.042, NS). 
 
Discussion  
The objectives of our study were to assess the relationship of handgrip with the other CARTs 
in the diagnosis of CAN as well as to identify the factors having influence on the diastolic BP 
response to sustained handgrip. 
According to our data, very low sensitivity and moderate specificity of the handgrip test vs 
definite diagnosis of CAN could be demonstrated. Results of the handgrip test did not show 
any association with results of the deep breathing test, 30/15 ratio and the partially 
sympathetically controlled Valsalva ratio. An association between results of the handgrip test 
and the OHT could not be proven. Potential confounding factors having influence on handgrip 
test outcomes were the presence of hypertension and baseline diastolic BP. 
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CAN is an early and frequent complication and is accompanied with poor prognosis among 
patients with DM. In epidemiological studies performed on patient populations with both type 
1 and type 2 DM, the prevalence rates of confirmed CAN ranged from 16.6 to 20% [14, 15]. 
The prevalence of CAN increases with age and DM duration reaching as high as 65% in 
patients with long-standing type 2 DM [16]. In our study, the prevalence rate of CAN based 
on the presence of ≥2 abnormal cardiovascular reflex tests was 37%. Considering age, DM 
duration and the proportion of type 2 DM patients in our study population, this prevalence is 
in accordance with the literature [1, 3, 6, 11, 13-14]. 
As CAN imposes an enormous increase in cardiovascular morbidity and mortality among 
patients with DM, early diagnosis and timely intervention with risk reduction strategies are 
crucial. Safe, non-invasive tests with high sensitivity and reasonable specificity are warranted. 
Cardiovascular reflex tests are widely used for identifying patients with CAN. In a study by 
Ewing et al. [17], a weak but significant correlation between the rise in diastolic BP in 
response to handgrip and Valsalva ratio was demonstrated. Patients with handgrip test 
abnormality had lower Valsalva ratio compared with those with normal handgrip test results 
[17]. When compared with spectral analysis of heart rate variability as a reference test, BP 
tests added on to heart rate tests did not improve diagnostic performance of CARTs [18]. 
Sustained handgrip test had significant weaker associations with LnLFDAY – a measure of 
prevalent sympathetic function – than OHT did [18]. However, particular reasons why the 
handgrip test has limited diagnostic performance remained elusive.  
In the present study, we confirmed that handgrip test has poor sensitivity and moderate 
specificity for diagnosing CAN. No associations between handgrip test results and other 
CART outcomes could be established. Furthermore, a negative association between handgrip 
test abnormality and hypertension was demonstrated showing that patients with both DM and 
hypertension are unlikely to exhibit reduced diastolic BP response to handgrip exercise. The 
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putative mechanism behind this phenomenon could be an exaggerated exercise pressor reflex 
related to increased sympathetic activation in patients with DM and hypertension. 
The exercise pressor reflex aims the adaptation of autonomic nerve control of the 
cardiovascular system during exercise to meet the perfusion and metabolic demand of 
working skeletal muscle. Static (isometric) exercise causes heart rate-dependent increases in 
cardiac output accompanied by increased or unchanged peripheral vascular resistance 
resulting in substantially elevated BP [19, 20]. There is emerging evidence that hypertension 
is associated with excessive pressor responses during muscle contraction; both mechanically 
(mechanoreflex) and metabolically (metaboreflex) driven components of the pressor reflex 
are suggested being involved [21, 22]. Patients with hypertension were shown to produce 
exaggerated BP elevation and enhanced muscle sympathetic nerve activation during isometric 
handgrip exercise compared with age-related healthy controls [23, 24]. Increased muscle 
metaboreflex activation leading to augmented pressor responses was demonstrated in older 
moderately hypertensive adults [25] and in pre-hypertensive state [26]. The exercise pressor 
reflex might occur promptly: BP elevation and heart rate increased within 30-60 sec during 
static contraction in an experimental study [27]. More than two-thirds of our patients with DM 
had hypertension; this exaggerated exercise pressor reflex might explain why abnormal 
handgrip test results were not commonly found in our patients, even if they may have been 
already affected by CAN. The inverse association between abnormality of the handgrip test 
and hypertension indicates that low sensitivity of the handgrip test might be the result of a 
‘masking effect’ of hypertension. 
Previously, both hypertension and DM were found to be associated with impaired autonomic 
function: they negatively influence most CARTs [28], baroreflex sensitivity and heart rate 
variability [29-31] with their effects being additive [32, 33]. Nevertheless, the handgrip test 
seems to be the only measure of CAN being conversely affected by DM and hypertension. 
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Hence, handgrip test outcomes might reflect the counteraction between increased sympathetic 
activity being a feature of essential hypertension and sympathetic impairment attributable to 
diabetic autonomic neuropathy. 
Hypertension is a frequent comorbidity of DM. Using ambulatory BP monitoring (ABPM), 
hypertension could be diagnosed in 54 and 29% of type 2 DM patients with/without CAN in 
spite of normal office BP and no history of hypertension [30]. In this context, hypertension 
may remain unrecognized in up to half of the patients with CAN [30]. Therefore, the effects 
of hypertension on handgrip test results cannot be overestimated in routine clinical practice. 
The known or unknown hypertension involving sympathetic overactivity prevents detecting 
CAN in the majority of our patients when sympathetic dysfunction is assessed by the 
handgrip test. 
Autonomic dysregulation characterized by sympathetic overactivity and parasympathetic 
impairment has been proposed as a mechanism of developing hypertension [34]. The role of 
baroreflex in attenuating the circulatory response to exercise has been recently described [35]. 
Consequently, one could speculate that augmented BP response to sustained muscular strain 
and hypertension itself may be at least partially compelled by parasympathetic impairment 
leading to ‘pseudo-normal’ handgrip test results in patients with diabetic neuropathy. 
In our study, diastolic BP changes in response to handgrip test were inversely correlated with 
baseline diastolic BP. The higher the baseline values were, the less was the extent of diastolic 
BP elevation and the greater was the chance of handgrip test abnormality. It would be 
conceivable that baseline diastolic BP is a limiting factor of diastolic BP increase during the 
test. Noteworthy, reduced diastolic BP as a consequence of increased central artery stiffness is 
a common feature of hypertension in the elderly. Hence, the association between lower 
diastolic BP and normal handgrip test results may be also attributed to atherosclerosis and 
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hypertension in our population. Still, the independent association between higher baseline 
diastolic BP values and handgrip test abnormality needs further investigation. 
The strength of the present study is the well-defined patient population. All drugs, especially 
antihypertensive agents being of potential influence on the outcomes of the cardiovascular 
reflex tests were included in the statistical analysis. Therefore, an independent inverse 
association between abnormality of the handgrip test and the presence of hypertension could 
be revealed. 
A limitation of this study could be the absence of information on physical activity. Muscle 
function might influence the pressor response during isometric exercise. However, the 
exclusion of patients with relevant comorbidities and poor physical status should have 
excluded those with significantly impaired muscle function. Moreover, overweight status of 
our patients was only assessed by calculating BMI that does not provide any information on 
the type of obesity. Visceral adipose tissue accumulation may contribute to sympathetic 
nervous system activation [36, 37]. Although no association between handgrip test results and 
BMI was found, the influence of visceral obesity on our results cannot be entirely excluded.  
The OHT test results were associated with measures of all three parasympathetic function 
tests, including the Valsalva ratio, confirming previous observations [38]. The association 
between OHT and abnormal Valsalva ratio is plausible, as OHT is an established test of 
sympathetic function as well, and circulatory changes during the Valsalva manoeuvre are also 
partially controlled by sympathetic pathways. The former association may be attributable to 
the fact that the possibility and extent of sympathetic impairment is expected to increase with 
severity of parasympathetic dysfunction. OHT was independent of anthropometric data and 
was neither influenced by the presence of hypertension nor by initial supine systolic BP 
suggesting that it is a reliable test. This latter finding is in contrast with previous observations 
that the magnitude of the orthostatic BP fall is related to the baseline supine BP with 25% of 
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the variance of the systolic BP fall being due to the supine BP [38, 39]. This discrepancy 
might be explained by the fact that systolic BP values in our patients were not very high and 
they were treated with antihypertensive medication. 
This topic has several important therapeutic implications. Alpha-lipoic acid, the most powerful 
pathogenetic therapeutic option of diabetic peripheral neuropathy [40-42] is also considered as 
the best choice for the treatment of CAN [43]. Alpha-lipoic acid enhances endoneurial blood 
flow by preventing the inhibition of nitric oxide synthetase and this way precludes ischaemic 
damage to nerve tissues [41]. Another pathogenetic option is the transketolase activator 
benfotiamine, inhibiting harmful alternative metabolic pathways, such as advanced glycation 
end product formation, the hexosamin and the protein-kinase-C pathways [44], as well as the 
polyol pathway [45].  
Our data indicate that the presence of hypertension was identified as the main confounder for 
the presence of a false negative handgrip test. The majority of patients with DM, especially 
those with autonomic neuropathy, have hypertension as well [30, 32, 36, 46, 47]. Most patients 
with DM and hypertension are treated with ACE inhibitors, while these drugs might have an 
effect on autonomic function as well. Didangelos et al. [48] assessed the effect of ACE 
inhibition or angiotensin receptor blockade, and their combination on CAN in patients with 
DM. After 12 months, improvement of CAN was observed in patients treated both with 
quinapril or losartan, while their combination was slightly even more effective [48]. Beneficial 
effect of quinapril on CAN has also been observed in another study [49], while no significant 
changes in CAN was detected after 12 months treatment with trandolapril [50]. 
In the context of parasympathetic-sympathetic imbalance, relative sympathetic overactivity 
influences the action of beta-blocking agents; cardioselective beta-blockers have a beneficial 
effect on cardiac autonomic dysfunction [51]. Our results confirm that assessment of orthostatic 
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BP changes should be considered as the only reliable measure of sympathetic nerve function. 
Some drugs, like hydrochlorothiazide, alpha- and non-selective beta-blocking agents might 
aggravate OHT, while beta-blockers with intrinsic sympathomimetic properties (partial 
agonists) have a role in the therapy of OHT. 
In summary, the handgrip test has low sensitivity for CAN and shows no association with the 
other reflex tests established for assessing CAN in DM. Our data provide evidence that the 
handgrip test should no longer be part of the cardiovascular autonomic testing being highly 
dependent on both the hypertensive status and baseline diastolic BP. Among these factors, the 
presence of hypertension seems to be decisive. Instead of measuring diastolic BP response to 
handgrip exercise, OHT test should be used for the evaluation of sympathetic dysfunction as 
recommended in the latest guidelines [1]. 
Adequate CARTs important to allow their use in clinical trials and for the prevention of DM-
associated complications by initiating early treatment.  
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Table 1.  
Main clinical characteristics of the study population. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Parameters (n=353) 
 
Mean age (years) 60.2±7.4* 
Gender (male/female) 151/202 
HbA1c 7.8±1.4% (61.2±15.8 mmol/mol)* 
Diabetes duration (years) 15.6±9.9* 
Type 1 / type 2 diabetes 64 (18%) / 289 (82%) 
BMI (kg/m2) 28.7 (25; 32)# 
Hypertension (yes/no) 225 (63.7%) / 128 (36.3%) 
Antihypertensive medication (n=225) 
ACEi or ARB/CCB/diuretics/AG 
174/87/151/40 
Statin use 160/353 (45%) 
Aspirin use 147/353 (42%) 
* mean ± SD 
# geometric mean (interquartile range) 
ACEi: ACE inhibitors; ARB: angiotensin receptor blockers,; 
CCB: calcium channel blocker. diuretics included 
hydrochlorothiazide and indapamide. AG: alpha1-receptor 
antagonists.  
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CARTs scores Handgrip score p 
Deep Breathing γ = 0.04 0.563 
Valsalva manoeuvre γ = 0.058 0.436 
30/15 ratio γ = 0.282 0.357 
Orthostatic hypotension γ = -0.026 0.833 
Parasympathetic score γ = 0.059 0.465 
 
OHT score p 
Deep Breathing 
γ = 0.219 0.046 
Valsalva manoeuvre 
γ = 0.311 0.006 
30/15 ratio 
γ = 0.470 0.059 
Parasympathetic score 
γ = 0.301 0.003 
γ = Monotony coefficient gamma 
Table 2. Associations between abnormality (i.e. score) of the handgrip test and the 
abnormalities of the other cardiovascular reflex tests (CARTs; for comparison, 
associations of orthostatic hypotension test (OHT) are also indicated). 
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Table 3. Comparison of demographic and clinical characteristics of diabetic subjects with or 
without handgrip test abnormality (univariate analysis). 
 
 
 
 
 
 
 
 
 
 
 
Abnormal handgrip test result 
(n=78) 
Normal handgrip 
test result 
(n=275) 
p  
Age (years) 58.8±12.6 60.6±12.5 0.224* 
BMI (kg/m2) 29.0±6.3 29.4±5.8 0.517* 
Diabetes duration (years) 10.9 (8; 20) 10.0 (6; 20) 0.573 
HbA1c (%) 7.8 ±1.4 7.7±1.5 0.340 
HbA1c (mmol/mol) 61.2±15.8 60.9±15.8 0.338* 
Confirmed diagnosis of CAN 32 (41.0%) 98 (36.6%) 0.384 # 
Deep Breathing (1/min) 8.94 (7; 13) 8.54 (6; 12) 0.510 
Valsalva ratio 1.27 (1.18; 1.32) 1.24 (1.17; 1.32) 0.507 
30/15 ratio 1.15 (1.09; 1.22) 1.17 (1.1; 1.22) 0.542 
Orthostatic hypotension 
(mmHg) 
6 (0; 12) 7 (2; 14) 0.988 
Parasympathetic score 2.94 (2; 4) 2.8 (2; 4) 0.527 
CAN score 3.33 (3; 4) 3.21 (2; 4) 0.468 
Diagnosis of hypertension 39 (50.0%) 186 (67.7%) 0.0076 # 
Office systolic blood pressure 
(mmHg) 
140 (126; 152) 130 (120; 144) 0.007 
Baseline diastolic blood 
pressure (mmHg) 
83 (76; 92) 78 (72; 86) 0.0004 
ACEi/ARB 43 (55.0%) 183 (66.5%) 0.087 # 
CCB 22 (28.2%) 65 (23.6%) 0.836 # 
Alfa receptor antagonist 7 (8.97%) 37 (13.5%) 0.023** 
Diuretics 25 (32.1%) 104 (37.8%) 0.046 # 
Insulin therapy 37 (47.4%) 134 (48.7%) 0.951 # 
Neuropathic pain 11 (14.0%) 35 (12.7%) 0.690 # 
Data are reported as mean + SD or geometric mean/median and interquartile range. Between-
group comparisons were carried out by Mann-Whitney U-test or two-sample t-test (*) where 
appropriate. 
# χ²-test or **Fisher’s exact test for categorical variables were used as indicated. Categorical data 
are reported as n (%). 
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Abbreviations: 
BMI: body mass index 
HbA1c: haemoglobin A1c 
CAN: cardiovascular autonomic neuropathy 
ACEi/ARB: angiotensin-convertase enzyme inhibitor/angiotensin receptor blocker 
CCB: calcium channel blocker
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Table 4. The relationship between handgrip test abnormality and hypertension as well as 
initial diastolic blood pressure values adjusted for the confounding antihypertensive 
medication (multiple logistic regression analysis). 
Variables p < 0.1 from table 4 are included in the analysis.  
 
 
 
Abbreviations: 
ACEi/ARB: angiotensin-convertase enzyme inhibitor/angiotensin receptor blocker 
 
 
 
 
 
 
 
 
OR 95% CI p 
Hypertension 0.42 0.23-0.78 0.006 
ACEi/ARB 0.96 0.49-1.84 0.909 
Alpha-receptor antagonists 1.04 0.42-2.59 0.931 
Diuretics 1.14 0.61-2.13 0.696 
Initial diastolic blood pressure 1.05 1.02-1.08 0.0009 
